Literature DB >> 32577845

Durable remission with ruxolitinib in a chronic neutrophilic leukemia patient harboring a truncation and membrane proximal CSF3R compound mutation.

Anna Hinze1, Jenny Rinke1, Andreas Hochhaus1, Thomas Ernst2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32577845      PMCID： PMC7817602          DOI： 10.1007/s00277-020-04152-w

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  9 in total

Review 1.  Chronic neutrophilic leukemia: 2018 update on diagnosis, molecular genetics and management.

Authors:  Michelle A Elliott; Ayalew Tefferi
Journal:  Am J Hematol       Date:  2018-08       Impact factor: 10.047

2.  Ruxolitinib, a potent JAK1/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent CSF3R mutations in chronic neutrophilic leukemia.

Authors:  Arief S Gunawan; Donal P McLornan; Bridget Wilkins; Katherine Waghorn; Yvette Hoade; Nicholas C P Cross; Claire N Harrison
Journal:  Haematologica       Date:  2017-03-16       Impact factor: 9.941

3.  Changes in allele frequencies of CSF3R and SETBP1 mutations and evidence of clonal evolution in a chronic neutrophilic leukemia patient treated with ruxolitinib.

Authors:  Zohra Nooruddin; Nicholas Miltgen; Qi Wei; Jeffrey Schowinsky; Zengang Pan; Jennifer Tobin; Enkhtsetseg Purev; Jonathan A Gutman; William Robinson; Daniel A Pollyea
Journal:  Haematologica       Date:  2017-02-16       Impact factor: 9.941

4.  Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia.

Authors:  Guido Marcucci; Klaus H Metzeler; Sebastian Schwind; Heiko Becker; Kati Maharry; Krzysztof Mrózek; Michael D Radmacher; Jessica Kohlschmidt; Deedra Nicolet; Susan P Whitman; Yue-Zhong Wu; Bayard L Powell; Thomas H Carter; Jonathan E Kolitz; Meir Wetzler; Andrew J Carroll; Maria R Baer; Joseph O Moore; Michael A Caligiuri; Richard A Larson; Clara D Bloomfield
Journal:  J Clin Oncol       Date:  2012-01-30       Impact factor: 44.544

5.  Defective internalization and sustained activation of truncated granulocyte colony-stimulating factor receptor found in severe congenital neutropenia/acute myeloid leukemia.

Authors:  A C Ward; Y M van Aesch; A M Schelen; I P Touw
Journal:  Blood       Date:  1999-01-15       Impact factor: 22.113

6.  Clinical response to ruxolitinib in CSF3R T618-mutated chronic neutrophilic leukemia.

Authors:  Maximilian Stahl; Mina L Xu; David P Steensma; Raajit Rampal; Melissa Much; Amer M Zeidan
Journal:  Ann Hematol       Date:  2016-04-11       Impact factor: 3.673

7.  Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia.

Authors:  Kim-Hien T Dao; Jason Gotlib; Michael M N Deininger; Stephen T Oh; Jorge E Cortes; Robert H Collins; Elliot F Winton; Dana R Parker; Hyunjung Lee; Anna Reister; Samantha Savage; Chase Brockett; Nan Subbiah; Richard D Press; Philipp W Raess; Michael Cascio; Jennifer Dunlap; Yiyi Chen; Catherine Degnin; Julia E Maxson; Cristina E Tognon; Tara Macey; Brian J Druker; Jeffrey W Tyner
Journal:  J Clin Oncol       Date:  2019-12-27       Impact factor: 44.544

8.  Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.

Authors:  Julia E Maxson; Jason Gotlib; Daniel A Pollyea; Angela G Fleischman; Anupriya Agarwal; Christopher A Eide; Daniel Bottomly; Beth Wilmot; Shannon K McWeeney; Cristina E Tognon; J Blake Pond; Robert H Collins; Basem Goueli; Stephen T Oh; Michael W Deininger; Bill H Chang; Marc M Loriaux; Brian J Druker; Jeffrey W Tyner
Journal:  N Engl J Med       Date:  2013-05-09       Impact factor: 91.245

9.  Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia.

Authors:  Liran I Shlush; Sasan Zandi; Amanda Mitchell; Weihsu Claire Chen; Joseph M Brandwein; Vikas Gupta; James A Kennedy; Aaron D Schimmer; Andre C Schuh; Karen W Yee; Jessica L McLeod; Monica Doedens; Jessie J F Medeiros; Rene Marke; Hyeoung Joon Kim; Kwon Lee; John D McPherson; Thomas J Hudson; Andrew M K Brown; Fouad Yousif; Quang M Trinh; Lincoln D Stein; Mark D Minden; Jean C Y Wang; John E Dick
Journal:  Nature       Date:  2014-02-12       Impact factor: 69.504
  9 in total
  5 in total

1.  B-lymphoblastic leukemia arising in a patient with chronic neutrophilic leukemia.

Authors:  Craig S Boddy; Brent T Tan; Joseph Aoki
Journal:  Blood Adv       Date:  2020-11-10

Review 2.  Chronic Neutrophilic Leukemia: A Comprehensive Review of Clinical Characteristics, Genetic Landscape and Management.

Authors:  Thomas P Thomopoulos; Argiris Symeonidis; Alexandra Kourakli; Sotirios G Papageorgiou; Vasiliki Pappa
Journal:  Front Oncol       Date:  2022-04-14       Impact factor: 5.738

3.  Anti-inflammatory effects of ruxolitinib on chronic neutrophilic leukemia harboring CSF3R-T618I mutation with bilateral renal abscesses.

Authors:  Naohi Sahara; Kazuaki Yokoyama; Takashi Matsunaga; Shinsuke Kitahara; Tomoki Fujii; Seiichiro Kobayashi; Nozomi Yusa; Eigo Shimizu; Seiya Imoto; Arinobu Tojo; Nobuhiro Ohno
Journal:  Leuk Res Rep       Date:  2022-09-06

Review 4.  Current Management of Chronic Neutrophilic Leukemia.

Authors:  Natasha Szuber; Ayalew Tefferi
Journal:  Curr Treat Options Oncol       Date:  2021-06-07

Review 5.  Chronic Neutrophilic Leukemia: A Literature Review of the Rare Myeloproliferative Pathology.

Authors:  Vishwanath Anil; Harpreet Gosal; Harsimran Kaur; Hyginus Chakwop Ngassa; Khaled A Elmenawi; Lubna Mohammed
Journal:  Cureus       Date:  2021-06-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.